Mikołaj Slabicki, PhD
Mikolaj Slabicki studied at the Technical University of Łódź, in Poland and performed his PhD under the guidance of Dr. Frank Buchholz at the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany. During his graduate studies, Mikolaj employed functional genomics to study the mechanism of double stranded DNA breaks and characterized a novel hereditary spastic paraplegia gene, SPG48.
Mikolaj pursued his post-doctoral research at the National Center for Tumor Diseases/ German Cancer Research Center in Heidelberg, where he identified CREM, MBD2 and CHD4 as novel CD20 modulators.
Mikolaj is currently a Marie Sklodowska Curie Scholar and a Research Fellow in Dr. Benjamin Ebert’s laboratory, in the Cancer Program at the Broad Institute, and the department of Medical Oncology at Dana-Farber Cancer in Boston, and in Stefan Fröhling laboratory at the German Cancer Research Center in Heidelberg. He is applying his functional genomics experience towards characterization of drug-induced degradation. His recent work led to the identification of the CDK inhibitor CR8 as a novel molecular glue degrader that targets cyclin K.